|
1
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amm HM, Oliver PG, Lee CH, Li Y and
Buchsbaum DJ: Combined modality therapy with TRAIL or agonistic
death receptor antibodies. Cancer Biol Ther. 11:431–449. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wakelee HA, Patnaik A, Sikic BI, Mita M,
Fox NL, Miceli R, Ullrich SJ, Fisher GA and Tolcher AW: Phase I and
pharmaco-kinetic study of lexatumumab (HGS-ETR2) given every 2
weeks in patients with advanced solid tumors. Ann Oncol.
21:376–381. 2010. View Article : Google Scholar :
|
|
4
|
Herbst RS, Eckhardt SG, Kurzrock R,
Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA,
Tohnya TM, Lum BL, et al: Phase I dose-escalation study of
recombinant human Apo2L/TRAIL, a dual proapoptotic receptor
agonist, in patients with advanced cancer. J Clin Oncol.
28:2839–2846. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R,
Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand
TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mérino D, Lalaoui N, Morizot A, Schneider
P, Solary E and Micheau O: Differential inhibition of
TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol
Cell Biol. 26:7046–7055. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu F, Hu Y, Long J, Zhou YJ, Zhong YH,
Liao ZK, Liu SQ, Zhou FX, Zhou YF and Xie CH: Cytotoxicity and
radiosensitization effect of TRA-8 on radioresistant human larynx
squamous carcinoma cells. Oncol Rep. 21:461–465. 2009.PubMed/NCBI
|
|
8
|
Johnston JB, Kabore AF, Strutinsky J, Hu
X, Paul JT, Kropp DM, Kuschak B, Begleiter A and Gibson SB: Role of
the TRAIL/APO2-L death receptors in chlorambucil- and
fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Oncogene. 22:8356–8369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Li Y, Wu Y, Shi K, Bing L and Hao
J: Wnt/β-catenin signaling pathway upregulates c-Myc expression to
promote cell proliferation of P19 teratocarcinoma cells. Anat Rec
(Hoboken). 295:2104–2113. 2012. View
Article : Google Scholar
|
|
11
|
Tanaka SS, Kojima Y, Yamaguchi YL,
Nishinakamura R and Tam PP: Impact of WNT signaling on tissue
lineage differentiation in the early mouse embryo. Dev Growth
Differ. 53:843–856. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Glass DA II, Bialek P, Ahn JD, Starbuck M,
Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, et al:
Canonical Wnt signaling in differentiated osteoblasts controls
osteoclast differentiation. Dev Cell. 8:751–764. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Toni EN, Thieme SE, Herbst A, Behrens
A, Stieber P, Jung A, Blum H, Göke B and Kolligs FT: OPG is
regulated by beta-catenin and mediates resistance to TRAIL-induced
apoptosis in colon cancer. Clin Cancer Res. 14:4713–4718. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Orford K, Crockett C, Jensen JP, Weissman
AM and Byers SW: Serine phosphorylation-regulated ubiquitination
and degradation of beta-catenin. J Biol Chem. 272:24735–24738.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rott R, Szargel R, Haskin J, Bandopadhyay
R, Lees AJ, Shani V and Engelender S: α-Synuclein fate is
determined by USP9X-regulated monoubiquitination. Proc Natl Acad
Sci USA. 108:18666–18671. 2011. View Article : Google Scholar
|
|
16
|
Taya S, Yamamoto T, Kanai-Azuma M, Wood SA
and Kaibuchi K: The deubiquitinating enzyme Fam interacts with and
stabilizes beta-catenin. Genes Cells. 4:757–767. 1999. View Article : Google Scholar
|
|
17
|
Park S, Shim SM, Nam SH, Andera L, Suh N
and Kim I: CGP74514A enhances TRAIL-induced apoptosis in breast
cancer cells by reducing X-linked inhibitor of apoptosis protein.
Anticancer Res. 34:3557–3562. 2014.PubMed/NCBI
|
|
18
|
Ouyang W, Yang C, Liu Y, Xiong J, Zhang J,
Zhong Y, Zhang G, Zhou F, Zhou Y and Xie C: Redistribution of DR4
and DR5 in lipid rafts accounts for the sensitivity to TRAIL in
NSCLC cells. Int J Oncol. 39:1577–1586. 2011.PubMed/NCBI
|
|
19
|
Wu Q, Zheng Y, Chen D, Li X, Lu C and
Zhang Z: Aberrant expression of decoy receptor 3 in human breast
cancer: Relevance to lymphangiogenesis. J Surg Res. 188:459–465.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Zhou J, Shi J, Zhang Y, Liu S, Liu
Y, Zheng D and Ross SR: Human T-cell leukemia virus type 1
Tax-deregulated autophagy pathway and c-FLIP expression contribute
to resistance against death receptor-mediated apoptosis. J Virol.
88:2786–2798. 2014. View Article : Google Scholar :
|
|
21
|
Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim
HR, Lotan R and Wu GS: Overexpression of BCL2 blocks TNF-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung
cancer cells. Biochem Biophys Res Commun. 280:788–797. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deng Y, Lin Y and Wu X: TRAIL-induced
apoptosis requires Bax-dependent mitochondrial release of
Smac/DIABLO. Genes Dev. 16:33–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cummins JM, Kohli M, Rago C, Kinzler KW,
Vogelstein B and Bunz F: X-linked inhibitor of apoptosis protein
(XIAP) is a nonredundant modulator of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human
cancer cells. Cancer Res. 64:3006–3008. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shin MS, Kim HS, Lee SH, Park WS, Kim SY,
Park JY, Lee JH, Lee SK, Lee SN, Jung SS, et al: Mutations of tumor
necrosis factor-related apoptosis-inducing ligand receptor 1
(TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast
cancers. Cancer Res. 61:4942–4946. 2001.PubMed/NCBI
|
|
25
|
King TD, Suto MJ and Li Y: The
Wnt/β-catenin signaling pathway: A potential therapeutic target in
the treatment of triple negative breast cancer. J Cell Biochem.
113:13–18. 2012. View Article : Google Scholar
|
